PETS

PetMed Express Inc. (PETS) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025 (First Quarter of Fiscal Year 2026). PetMed Express, Inc. operates as a leading direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, and veterinary services. The Company's fiscal year ends on March 31.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 22.7% year-over-year, driven by a 21.8% drop in reorder sales and a 25.6% drop in new order sales. Management attributed this to reduced gross advertising spend and higher consumer promotional usage.
• Significant Impairment Charge: The Company recorded a non-cash impairment charge of $27.3 million ($26.7 million goodwill and $0.6 million intangible assets). This was triggered by a downward revision to forecasts and a sustained decline in market capitalization below the carrying value of assets.
• Restatement of Prior Period: Financial statements for the quarter ended June 30, 2024, were restated to correct material errors regarding the accounting of vendor-funded programs (reclassifying certain reimbursements from revenue to cost of sales and reclassifying advertising expenses).
• Operating Expenses: General and administrative expenses increased 165.7% to $12.9 million, primarily due to a reversal of stock-based compensation in the prior year and increased professional fees related to an internal investigation.
• Liquidity: Cash and cash equivalents decreased by $13.6 million during the quarter, with net cash used in operating activities totaling $12.3 million.

Guidance, Outlook, and Risks

• Management Commentary: The Company does not provide specific forward-looking financial guidance in this filing. Management noted that macroeconomic factors, including inflation and rising interest rates, continue to impact consumer demand and forecasting.
• Executive Changes: Subsequent to the period end, the CEO (Sandra Campos) and CFO (Robyn D'Elia) resigned on August 11, 2025. Leslie C.G. Campbell was appointed Interim CEO, and Doug Krulik was appointed Interim CFO.
• Acquisition Proposals: In December 2025, the Company received unsolicited, non-binding acquisition proposals ranging from $4.00 to $4.25 per share. The Board is reviewing these proposals.
• Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to unremediated material weaknesses in internal control over financial reporting.
• Legal Proceedings: The Company is defending a class action lawsuit regarding alleged "illusory discounts" on product pricing. No liability has been recorded as the outcome is uncertain.

Investor Verification Checklist

• Impairment Validity: Verify the assumptions used in the discounted cash flow model for the $27.3 million goodwill and intangible asset impairment, specifically the discount rate (14.0%) and terminal growth rate (3%).
• Restatement Impact: Review the full details of the accounting error correction regarding vendor reimbursements to understand the true historical profitability trends.
• Liquidity Runway: Assess the sustainability of operations given the $12.3 million cash burn in the quarter and the suspension of dividends, despite the $41.1 million cash balance.
• Internal Controls: Monitor the remediation plan for the material weaknesses in internal controls over financial reporting, which led to the restatement.
• Acquisition Status: Track the Board's response to the unsolicited acquisition proposals and any potential impact on share price or strategic direction.